Angiotensin II‐dependent loss of cardiac function: Mechanisms and pharmacological targets attenuating this effect
- 4 June 2008
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 217 (1) , 242-249
Abstract
Pharmacological inhibition of components of the renin‐angiotensin‐system is one of the major therapeutically options to treat patients with heart failure. This study hypothesized that angiotensin II (Ang II) directly depresses contractile function (cell shortening) by activation of transforming growth factor‐β1 (TGF‐β1). Moreover, we hypothesized that an inhibition of glycogen synthase kinase 3‐βGSK will compensate for this depressive effect by increasing SERCA2 expression. Isolated adult ventricular rat cardiomyocytes were used and cultured in the presence of Ang II (100 nM) for 24 h. Cell shortening and contractile dynamics were recorded at 2 Hz. Immunoblot techniques and gel mobility shift assays were used to demonstrate NFAT activation caused by inhibition of GSK and to demonstrate increases in the expression of SERCA2. Ang‐II caused a nearly 20% decrease in cell shortening. This Ang II‐dependent effect was mimicked by TGF‐β1 (10 ng/ml), attenuated by addition of aprotinin, that was used to block the proteolytic activation of TGF‐β1, or by application of a neutralizing antibody directed against TGF‐β1. Inhibition of GSK activated NFAT, increased SERCA2 expression and improved cell function. In conclusion, the study identified a paracrine mechanism for the Ang II‐dependent loss of cardiac function that occurs independently of hemodynamic changes. Furthermore, it characterized the differences between Ang II and α‐adrenoceptor stimulation with respect to the maintenance of cellular function explaining cellular events contributing to the difference between adaptive (physiological) and mal‐adaptive (patho‐physiological) hypertrophy. J. Cell. Physiol. 217: 242–249, 2008.Keywords
This publication has 46 references indexed in Scilit:
- TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophyThe EMBO Journal, 2006
- The Positive Inotropic Effect of Angiotensin IIHypertension, 2006
- Angiotensin II–Mediated Phenotypic Cardiomyocyte Remodeling Leads to Age-Dependent Cardiac Dysfunction and FailureHypertension, 2005
- Inhibition of Ca2+-dependent PKC isoforms unmasks ERK-dependent hypertrophic growth evoked by phenylephrine in adult ventricular cardiomyocytes*1Cardiovascular Research, 2004
- Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3The Journal of Pharmacology and Experimental Therapeutics, 2003
- Negative inotropic effects of angiotensin II, endothelin-1 and phenylephrine in indo-1 loaded adult mouse ventricular myocytesLife Sciences, 2002
- SERCA Pump Level is a Critical Determinant of Ca2+Homeostasis and Cardiac ContractilityJournal of Molecular and Cellular Cardiology, 2001
- Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor β 1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 RatHypertension, 2000
- Angiotensin II and phorbol esters depress cardiac performance and decrease diastolic and systolic [Ca2+]i in isolated perfused rat heartsAmerican Heart Journal, 1991
- Effects of angiotensin II on membrane current in cardiac Purkinje fibersJournal of Molecular and Cellular Cardiology, 1981